Recombinant heregulin-pseudornonas exotoxin fusion proteins: Interactions with the heregulin receptors and antitumor activity in vivo

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 993-1004

  Yang, Dajun ^a,b   Kuan, Chien Tsun ^c   Payne, Jeniffer ^a   Kihara, Ako ^c   Murray, Ann ^a   Wang, Ling Mei ^c   Alimandi, Maurizio ^c   Pierce, Jacalyn H ^c   Pastan, Ira ^c   Lippman, Marc E ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; NEU DIFFERENTIATION FACTOR; PROTEIN; PROTEIN TYROSINE KINASE; PSEUDOMONAS EXOTOXIN; RECEPTOR; RECOMBINANT PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EXOTOXIN; GLYCOPROTEIN; HAR TX BETA 2 PROTEIN, RECOMBINANT; HAR-TX BETA 2 PROTEIN, RECOMBINANT; IMMUNOTOXIN; ONCOPROTEIN; TYROSINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LD 50; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; ANIMAL; CARCINOMA; CELL CULTURE; CLONOGENIC ASSAY; DRUG EFFECT; METABOLISM; NUDE MOUSE; PROTO ONCOGENE; STOMACH TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; COLONY-FORMING UNITS ASSAY; EXOTOXINS; FEMALE; GENES, ERBB; GLYCOPROTEINS; HUMANS; IMMUNOTOXINS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RECOMBINANT FUSION PROTEINS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0031596674     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hynes, N. E., and Stern, D. F. The biology of erbb-2/neu/her-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
2. Dougall, W. C., Zian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9: 2109-2123, 1994.
3. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
4. Paik, S., Haza, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., and King, C. R. Pathological findings from National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol., 8: 103-112, 1990.
5. Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., and Home, C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49: 2087-2090, 1989.
6. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1988.
7. Kraus, M., Issing, W., Miki, T., Popescu, N., and Aaronson, S. Isolation and characterization of erbB-3, a third member of the erbB epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 9193-9197, 1989.
8. Plowman, G., Whitney, G., Neubauer, M., Green, J. M., McDonald, V. L., Todaro, G. J., and Shoyab, M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl. Acad. Sci. USA, 87: 4905-4909, 1990.
9. erbB-4 a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
10. Lemoine, N. R., Barnes, D. M., Hollywood, D. P., Hughes, C. M., Smith, P. Dublin, E., Prigent, S. A., Gullick, W. J., and Hurst, H. C. Expression of C-erbB-3 gene product in breast cancers. Br. J. Cancer, 66: 1116-1121, 1992.
11. Quinn, C. M., Ostrowski, J. L., Lane, S. A., Loney, D. P., Teasdale, J., and Benson, F. A. c-erbB-3 protein expression in human breast: comparison with other tumor variables and survival. Histopathology (Oxford), 25: 247-252, 1994.
12. Gasparini, G., Gullick, W. J., Maluta, S., Palma, P. D., Caffo, O., Leonardi, E., Boracchi, P., Poza, F., Lemoine, N. R., and Bevilacqua, P. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma: an immunohistochemical study. Eur. J. Cancer, 30A: 16-22, 1994.
13. Simpson, B. J., Weatherill, J., Miller, E. P., Lessells, A. M., Langdon, S. P., and Miller, W. R. C-erbb-3 protein expression in ovarian tumours. Br. J. Cancer, 71: 758-762, 1995.
14. Myers, R. B., Srivastava, S., Oelschlager, D. K., and Grizzle, W. E. Expression of p160erbb-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 86: 1140-1145, 1994.
15. Lupu, R., Colomer, R., Zugmaier, G., Shepard, M., Slamon, D., and Lippman, M. E. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (Washington DC), 249: 1552-1555, 1990.
16. Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., Shepard H. M., Kuang, W., Wood, W. I., Goeddel, D. V., and Vandlen, R. L. Identification of heregulin, a specific activator of p185erbB2. Science (Washington DC), 256: 1205-1210, 1992.
17. Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., and Yarden, Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell, 69: 205-216, 1992.
18. Falls, D. L., Rosen, K. M., Corfas, G., Lane, W. S., and Fischbach, G. D. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell, 72: 801-815, 1993.
19. Marchionni, M. A., Goodearl, A. D. J., Chen, M. S., Bermingham-McDonogh, O., Kirk, C., Hendricks, M., Danehy, F., Misumi, D., Sudhalter, J., Kobayashi, K., Wroblewski, D., Lynch, C., Baldassare, M., Hiles, I., Davis, J. B., Hsuan, J. J., Totty, N. F., Otsu, M., McBurney, R. N., Waterfield, M. D., Stroobant, P., and Gwynne, D. Glial growth factors are alternatively spliced erbB-2 ligands expressed in the nervous system. Nature (Lond.), 362: 312-318, 1993.
20. Barbacci, E. G., Guarino, B. C., Stroh, J. G., Singleton, D. H., Rosnack, K. J., Moyer, J. D., and Andrews, G. C. The structural basis for the specificity of epidermal growth factor and heregulin binding. J. Biol. Chem., 270: 9585-9589, 1995.
21. Peles, E., and Yarden, Y. Neu and its ligand: from an oncogene to neural factors. BioEssays, 15: 815-824, 1993.
22. Carraway, K. L.,III, and Cantley, L. C. A neu acquaintance for erbB-3 and erbB-4: a role for receptor heterodimerization in growth signaling. Cell, 78: 5-8, 1994.
23. Carraway, K. L., III, Soltoff, S. P., Diamonti, A. J., and Cantley, L. C. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbb2/neu and erbb3. J. Biol. Chem., 270: 7111-7116, 1995.
24. Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III. Coexpression of erbb2 and erbb3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 269: 14661-14665, 1994.
25. Carraway, K. L., III, Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., and Cerione, R. A. The erbb3 gene product is a receptor for heregulin. J. Biol. Chem., 269: 14303-14306, 1994.
26. Kita, Y. A., Barff, J., Luo, Y., Wen, D., Brankow, D., Hu, S., Liu, N., Prigent, S. A., Gullick, W. J., and Nicolson, M. NDF/heregulin stimulates the phosphorylation of her3/erbb3. FEBS Lett., 349: 139-143, 1994.
27. Tzahar, E., Levkowitz, G., Karunagaran, D., Yi, L., Peles, E., Lavi, S., Chang, D., Liu, N., Yayon, A., Wen, D., and Yarden Y. Erbb-3 and erbb-4 function as the respective low and high affinity receptors of all neu differentiation factor/heregulin isoforms. J. Biol. Chem., 269: 25226-25233, 1994.
28. Plowman, G. D., Green, J. M., Culouscou, J. M., Carlton, G. W., Rothwell, V. M., and Buckley, S. Heregulin induces tyrosine phosphorylation of her4/p180erbb4. Nature (Lond.), 366: 473-475, 1993.
29. Chen, X., Levkowitz, G., Tzahar, E., Karunagaran, D., Lavi, S., Ben-Baruch, N., Leitner, O., Tatzkin, B. J., Bacus, S. S., and Yarden, Y. An immunological approach reveals biological differences between the two NDF/Heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem., 271: 7620-7629, 1996.
30. Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., and Yoshinaga, S. K. Transformation of NIH3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem., 271: 3884-3890, 1996.
31. Pai, L. H., and Pastan, I. Immunotoxins and recombinant toxins for cancer treatment. Important Adv. Oncol., 3-19, 1994.
32. Seetharam, S., Chaudhary, V. K., FitzGerald, D., and Pastan, I. Increased cytotoxic activity of Pseudomonas endotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem., 266: 17376-17381, 1991.
33. Goldberg, M. R., Heimbrook, D. C., Russo, P., Sarosdy, M. F., Greenberg, R. E., Giantonio, B. J., Linehan, M. W., Walther, M., Fisher, H. A. G., Messing, E., Crawford, E. D., Oliff, A. I., and Pastan, I. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res., 1: 57-61, 1995.
34. Kihara, A., and Pastan, I. Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res., 55: 71-77, 1995.
35. Park, J-G., Frucht, H., LaRocca, R. V., Bliss, D. P., Kurita, Y., Chen, T. R., Henslee, J. G., Trepel, J. B., Jensen, R. T., Johnson, B. E., Bang, Y-J., Kim, J-P., and Gazdar, A. Characteristics of cell lines established from human gastric carcinoma. Cancer Res., 50: 2773-2780, 1990.
36. Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M. M., and Clarke, R. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br. J. Cancer, 73: 154-161, 1996.
37. Alley, M., Scudiero, D., Monks, A., Hursey, M., Czerwinski, M., Fine, D., Abbott, B., Mayo, J., Shoemaker, R., and Boys, M. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
38. Wen, D., Suggs, S.V., Karunagaran, D., Liu, N., Cupples, R. L., Luo, Y., Janssen, A. M., Ben-Baruch, N., Trollinger, D. B., Jacobsen, V. L., Meng, S., Lu, H. S., Hu, S., Chang, D., Yang, W., Yanigahara, D., Koski, R. A., and Yaden, Y. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell. Biol., 14: 1909-1919, 1994.
39. Post. J., Vooys, W. C., Degast, G. C., and Bast, B. J. E. G. Comparison of various in vitro assays for efficacy screening of immunotoxins. Leuk. Res., 19: 241-247, 1995.
40. Pai, L. H., Gallo, M. G., Fitzgerald, D. J., and Pastan, I. Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res., 51: 2808-2812, 1991.
41. Kihara, A., and Pastan, I. Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor a. Bioconj. Chem., 5: 532-538, 1994.
42. Kihara, A., and Pastan, I. Small chimeric toxins containing only transforming growth factor and domain III of Pseudomonas exotoxin with good antitumor activity in mice. Cancer Res., 54: 5154-5159, 1994.
43. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
44. Wels, W., Harwerth, I. M., Mueller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbb-2 receptor. Cancer Res., 52: 6310-6317, 1992.
45. Siegall, C. B., Bacus, S. S., Cohen, B. D., Plowman, G. D., Mixan, B., Chace, D., Chin, D. M., Goetze, A., Green, J. M., Hellstrom, I., Hellstrom, K. E., and Fell, H. P. Her4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J. Biol. Chem., 270: 7625-7630, 1995.
46. Jeschke, M., Weis, W., Dengler, W., Imber, R., Stocklin, E., and Groner, B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer, 60: 730-739, 1995.
47. Marikovsky, M., Lavi, S., Pinkas-Kramarski, R., Karunagaran, D., Liu, N., Wen, D., and Yarden, Y. Erbb-3 mediates differential mitogenic effects of ndf/heregulin isoforms on mouse keratinocytes. Oncogene, 10: 1403-1411, 1995.
48. Di Fiore, P. P., Segatto, O., Taylor, W. G., Aaronson, S. A., and Pierce, J. H. EGF-receptor and erbB-2 tyrosine kinase domains confer cell specifically for mitogenic signaling. Science (Washington DC), 248: 79-83, 1990.
49. Alimandi, M., Wang, L. M., Bottaro, D., Lee, C. C., Kuo, A., Frankel, M., Fedi, P., Tang, C., Lippman, M. E, and Pierce, J. H. Epidermal growth factor and betacellulin mediate signal transduction through co-expression ErbB2 and ErbB3 receptors. EMBO J., 16: 5608-5617, 1997.
50. Beerli, R. R., Graus-Porta, D, Woods-Cook, K., Chem, X., Yarden, Y., and Hynes, N. E. Neu differentiation factor activation of erbB-3 and erbB-4 is cell specific and displays a differential requirement for erbB-2. Mol. Cell. Biol., 15: 6469-6505, 1995.
51. Wells, A., Welsh, J. B., Lazar, C. S., Wiley, H. S., Gill, G. N., and Rosenfeld, M. G. Ligand-induced transformation by a noninternalization epidermal growth factor receptor. Science (Washington DC), 247: 962-964, 1990.
52. Xu, F. J., Boyer, C. M., Bae, D. S., Wu, S., Greenwald, M., O'Briant, K., Yu, Y. H., Mills, G. B., and Bast, R. C., Jr. The tyrosine kinase activity of the c-erbb-2 gene product (pi85) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-a chain immunotoxin. Int. J. Cancer, 59: 242-247, 1994.
53. Horssen, P. J. V., Van Oosterhout, Y. V. J. M., De Witte, T., and Preijers, F. W. M. B. Cytotoxicity potency of CD22-ricin depends on intracellular routing rather than on the number of internalized moleculae. Scand. J. Immunol., 41: 563-569, 1995.
54. y immunotoxin not requiring proteolytic activation. Proc. Natl. Acad. Sci. USA, 93: 974-978, 1996.
55. Baselga, J., Norton, L., Coplan, K., Shalaby, R., and Mendelson, J. Antitumor activity of paclitaxel in combination with antigrowth factor receptor monoclonal antibodies in breast cancer xenografts. Proc. Am. Assoc. Cancer Res., 35: A2262, 1994.
56. Baselga, J., Norton, L., Masui, H., Coplan, K., Miller, W. H., and Mendelson, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer. Inst. (Bethesda), 85: 1327-1333, 1993.
57. King, C. R., Kasperzyk, P. G., Fisher, P. H., Bird, R. E., and Turner, N. A. Preclinical testing of an anti-erbB-2 recombinant toxin. Breast Cancer Res. Treat., 38: 19-25, 1996.